What's in a name? That which we call IPF, by any other name would act the same

What is it about?

In this perspective we address two issues. We rebut the recent suggestion that the name "IPF" should be changed, discussing the arguements for and against a name change. More importantly, we focus on future directions in IPF research and clinical practice. We highlight the potential value of amalgamating IPF with other lung disorders in which there is similar worsening lung damge, often leading to death. This approach may help us to a better understanding of scarring ("fibrotic") lung disorders and allow them to be treated by successful IPF drugs.

Featured Image